127 related articles for article (PubMed ID: 21054535)
1. Re: Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.
Kittleson MD; Bonagura JD
J Vet Intern Med; 2010; 24(6):1245-6; author reply 1247-8. PubMed ID: 21054535
[No Abstract] [Full Text] [Related]
2. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease.
Bernay F; Bland JM; Häggström J; Baduel L; Combes B; Lopez A; Kaltsatos V
J Vet Intern Med; 2010; 24(2):331-41. PubMed ID: 20102506
[TBL] [Abstract][Full Text] [Related]
3. Influence of combined angiotensin-converting enzyme inhibitors and spironolactone on serum K+, Mg 2+, and Na+ concentrations in small dogs with degenerative mitral valve disease.
Thomason JD; Rockwell JE; Fallaw TK; Calvert CA
J Vet Cardiol; 2007 Nov; 9(2):103-8. PubMed ID: 17983885
[TBL] [Abstract][Full Text] [Related]
4. Pharmacologic management of myxomatous mitral valve disease in dogs.
Atkins CE; Häggström J
J Vet Cardiol; 2012 Mar; 14(1):165-84. PubMed ID: 22386553
[TBL] [Abstract][Full Text] [Related]
5. An update on treatment and prognostic indicators in canine myxomatous mitral valve disease.
Häggström J; Höglund K; Borgarelli M
J Small Anim Pract; 2009 Sep; 50 Suppl 1():25-33. PubMed ID: 19765217
[TBL] [Abstract][Full Text] [Related]
6. Geriatric heart diseases in dogs.
Hamlin RL
Vet Clin North Am Small Anim Pract; 2005 May; 35(3):597-615. PubMed ID: 15833561
[TBL] [Abstract][Full Text] [Related]
7. Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study.
Lefebvre HP; Ollivier E; Atkins CE; Combes B; Concordet D; Kaltsatos V; Baduel L
J Vet Intern Med; 2013; 27(5):1083-91. PubMed ID: 23869534
[TBL] [Abstract][Full Text] [Related]
8. Increased NT-proANP predicts risk of congestive heart failure in Cavalier King Charles spaniels with mitral regurgitation caused by myxomatous valve disease.
Eriksson AS; Häggström J; Pedersen HD; Hansson K; Järvinen AK; Haukka J; Kvart C
J Vet Cardiol; 2014 Sep; 16(3):141-54. PubMed ID: 25130405
[TBL] [Abstract][Full Text] [Related]
9. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study.
Häggström J; Boswood A; O'Grady M; Jöns O; Smith S; Swift S; Borgarelli M; Gavaghan B; Kresken JG; Patteson M; Ablad B; Bussadori CM; Glaus T; Kovacević A; Rapp M; Santilli RA; Tidholm A; Eriksson A; Belanger MC; Deinert M; Little CJ; Kvart C; French A; Rønn-Landbo M; Wess G; Eggertsdottir AV; O'Sullivan ML; Schneider M; Lombard CW; Dukes-McEwan J; Willis R; Louvet A; DiFruscia R
J Vet Intern Med; 2008; 22(5):1124-35. PubMed ID: 18638016
[TBL] [Abstract][Full Text] [Related]
10. Use of human spironolactone in dogs with heart failure.
Broadfoot F; McGuire P
Vet Rec; 2008 Apr; 162(14):460. PubMed ID: 18390864
[No Abstract] [Full Text] [Related]
11. Hydralazine Therapy for severe mitral regurgitation in a dog.
Kittleson MD; Hamlin RL
J Am Vet Med Assoc; 1981 Nov; 179(9):903-5. PubMed ID: 7341606
[No Abstract] [Full Text] [Related]
12. Use of human spironolactone in dogs with heart failure.
Watson P
Vet Rec; 2008 May; 162(18):599. PubMed ID: 18453386
[No Abstract] [Full Text] [Related]
13. Use of human spironolactone in dogs with heart failure.
Whitehead M
Vet Rec; 2008 May; 162(18):599. PubMed ID: 18453385
[No Abstract] [Full Text] [Related]
14. Oral hydralazine therapy for chronic mitral regurgitation in the dog.
Kittleson MD; Eyster GE; Olivier NB; Anderson LK
J Am Vet Med Assoc; 1983 Jun; 182(11):1205-9. PubMed ID: 6863134
[No Abstract] [Full Text] [Related]
15. Pathology of myxomatous mitral valve disease in the dog.
Fox PR
J Vet Cardiol; 2012 Mar; 14(1):103-26. PubMed ID: 22386587
[TBL] [Abstract][Full Text] [Related]
16. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases.
Kittleson M; Rishniw M; Pion P
J Vet Intern Med; 2009; 23(3):445-6; author reply 447-8. PubMed ID: 19645830
[No Abstract] [Full Text] [Related]
17. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: A retrospective study of 141 cases.
Kittleson M; Rishniw M; Pion P; Kass P
J Vet Intern Med; 2009; 23(5):953-4; author reply 955-6. PubMed ID: 19737176
[No Abstract] [Full Text] [Related]
18. Chordae tendineae rupture in dogs with degenerative mitral valve disease: prevalence, survival, and prognostic factors (114 cases, 2001-2006).
Serres F; Chetboul V; Tissier R; Sampedrano CC; Gouni V; Nicolle AP; Pouchelon JL
J Vet Intern Med; 2007; 21(2):258-64. PubMed ID: 17427386
[TBL] [Abstract][Full Text] [Related]
19. Echocardiographic predictors of survival in dogs with myxomatous mitral valve disease.
Sargent J; Muzzi R; Mukherjee R; Somarathne S; Schranz K; Stephenson H; Connolly D; Brodbelt D; Fuentes VL
J Vet Cardiol; 2015 Mar; 17(1):1-12. PubMed ID: 25586168
[TBL] [Abstract][Full Text] [Related]
20. Long-term effect of sildenafil on echocardiographic parameters in dogs with asymptomatic myxomatous mitral valve degeneration.
Kijtawornrat A; Komolvanich S; Saengklub N; Pirintr P; Boonpala P; Buranakarl C
J Vet Med Sci; 2017 Apr; 79(4):788-794. PubMed ID: 28302926
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
